Education and Training

Awards and Honors

• CureSearch for Children's Cancer Acceleration Initiative Award, 2024.
• Elected Member, American Society for Clinical Investigation (ASCI), 2024.
• Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Medical Research Award, 2022.
• American Urological Association Early-Career investigators Showcase, Third Place, 2021.
• Atomwise Artificial Intelligence Molecular Screen (AIMS) Award, 2021.
• Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Innovation Award, 2021.
• NCI Experimental Therapeutics (NExT) Program Top Tier Application and Partnership, 2021.
• NIH Director's New Innovator (DP2) Award, 2021.
• Robert & Susan Hollander Foundation Research Award, 2021.
• American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award, 2020.
• Society for Basic Urologic Research (SBUR) Young Investigator Award, 2020.
• Movember Foundation-Prostate Cancer Foundation (PCF) Challenge Award, 2019.
• Safeway Early Career Award in Cancer Research, 2019.
• Society for Basic Urologic Research (SBUR) Eula and Donald S. Coffey Innovative Research Award, 2019.
• Lori Milken-Prostate Cancer Foundation (PCF) Young Investigator Award, 2015.

Publications

1. Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y, Zhang C, Flores D, Rodansky E, Swaim OA, Storck WK, Beck HN, Patel RA, Sayar E, Hanratty BP, Xue H, Dong X, Maylin ZR, Wan R, Quigley DA, Sjöström M, Hu YM, Zhao F, Xia Z, Cheng S, Yu X, Feng FY, Zhang L, Aggarwal R, Small EJ, Ravikumar V, Rao A, Bedi K, Lee JK, Morrissey C, Coleman I, Nelson PS, Corey E, Udager AM, Rebernick RJ, Cieslik MP, Chinnaiyan AM, Yates JA, Haffner MC, Wang Y, Alumkal JJ. PROX1 is an early driver of lineage plasticity in prostate cancer.. The Journal of clinical investigation, 2025.
2. Li S, Song K, Sun H, Tao Y, Huang A, Bhatia V, Hanratty B, Patel RA, Long HW, Morrissey C, Haffner MC, Nelson PS, Graeber TG, Lee JK. Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer.. bioRxiv : the preprint server for biology, 2025.
3. Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.. Frontiers in immunology, 2025.
4. Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.. Proceedings of the National Academy of Sciences of the United States of America, 2024.
5. Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Persse T, Galipeau P, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.. NPJ precision oncology, 2024.
6. Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam HM, Hsieh AC, Faltas BM, Haffner MC, Lee JK. A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nature genetics, 2024.
7. Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.. Cancer research communications, 2023.
8. Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit R, Coleman I, Lee JK, Nelson PS, Capaldo BJ, Mariani A, Hoover C, Senatorov IS, Beshiri M, Sowalsky AG, Hurt EM, Kelly K. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.. The Journal of clinical investigation, 2023.
9. Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, Morrissey C. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.. The Prostate, 2023.
10. Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, Alumkal JJ. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.. JCI insight, 2023.
11. Lee EHJ, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, Gumber D, Park AK, Young C, Monroy I, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chang WC, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.. Nature communications, 2023.
12. Zhou Z, Jia D, Kwon O, Li S, Sun H, Roudier MP, Lin DW, True L, Morrissey C, Creighton CJ, Lee JK, Xin L. Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.. Oncogene, 2023.
13. Ghali F, Vakar-Lopez F, Roudier MP, Garcia J, Arora S, Cheng HH, Schweizer MT, Haffner MC, Lee JK, Yu EY, Grivas P, Montgomery B, Hsieh AC, Wright JL, Lam HM. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.. Clinical genitourinary cancer, 2023.
14. Chour W, Choi J, Xie J, Chaffee ME, Schmitt TM, Finton K, DeLucia DC, Xu AM, Su Y, Chen DG, Zhang R, Yuan D, Hong S, Ng AHC, Butler JZ, Edmark RA, Jones LC, Murray KM, Peng S, Li G, Strong RK, Lee JK, Goldman JD, Greenberg PD, Heath JR. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis.. Communications biology, 2023.
15. Mao Z, Lee JK. Expanding the landscape of TCR gene therapy targeting MAGE.. Molecular therapy oncolytics, 2023.
16. Jana S, Brahma S, Arora S, Wladyka CL, Hoang P, Blinka S, Hough R, Horn JL, Liu Y, Wang LJ, Depeille P, Smith E, Montgomery RB, Lee JK, Haffner MC, Vakar-Lopez F, Grivas P, Wright JL, Lam HM, Black PC, Roose JP, Ryazanov AG, Subramaniam AR, Henikoff S, Hsieh AC. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.. Cancer cell, 2023.
17. Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Montgomery RB, Wright JL, Lam HM, Hsieh AC, Faltas BM, Haffner MC, Lee JK. Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations.. bioRxiv : the preprint server for biology, 2023.
18. Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.. Nature communications, 2023.
19. Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.. JCI insight, 2023.
20. Xu AM, Chour W, DeLucia DC, Su Y, Pavlovitch-Bedzyk AJ, Ng R, Rasheed Y, Davis MM, Lee JK, Heath JR. Entropic analysis of antigen-specific CDR3 domains identifies essential binding motifs shared by CDR3s with different antigen specificities.. Cell systems, 2023.
21. Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.. JCO precision oncology, 2023.
22. Low JY, Ko M, Hanratty B, Patel RA, Bhamidipati A, Heaphy CM, Sayar E, Lee JK, Li S, De Marzo AM, Nelson WG, Gupta A, Yegnasubramanian S, Ha G, Epstein JI, Haffner MC. Genomic Characterization of Prostatic Basal Cell Carcinoma.. The American journal of pathology, 2022.
23. Mao Z, Nesterenko PA, McLaughlin J, Deng W, Burton Sojo G, Cheng D, Noguchi M, Chour W, DeLucia DC, Finton KA, Qin Y, Obusan MB, Tran W, Wang L, Bangayan NJ, Ta L, Chen CC, Seet CS, Crooks GM, Phillips JW, Heath JR, Strong RK, Lee JK, Wohlschlegel JA, Witte ON. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.. Proceedings of the National Academy of Sciences of the United States of America, 2022.
24. Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low JY, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC. Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.. Cancer research communications, 2022.
25. DeLucia DC, Lee JK. Development of Cancer Immunotherapies.. Cancer treatment and research, 2022.
26. Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, Duke F, Chen J, Fung I, Watson J, Rees M, Gabel AM, Thomas JD, Bradley RK, Lee JK, Hatch EM, Baine MK, Rekhtman N, Ladanyi M, Piccioni F, Berger AH. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.. Nature communications, 2021.
27. Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.. Cancer research, 2021.
28. Kamat NV, Yu EY, Lee JK. BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021.
29. Cai EY, Garcia J, Liu Y, Vakar-Lopez F, Arora S, Nguyen HM, Lakely B, Brown L, Wong A, Montgomery B, Lee JK, Corey E, Wright JL, Hsieh AC, Lam HM. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.. Scientific reports, 2021.
30. Diamantopoulos LN, Sekar RR, Holt SK, Khaki AR, Miller NJ, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.. Urologic oncology, 2021.
31. DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
32. Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.. Clinical genitourinary cancer, 2020.
33. Kwon OJ, Zhang L, Jia D, Zhou Z, Li Z, Haffner M, Lee JK, True L, Morrissey C, Xin L. De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc.. Oncogene, 2020.
34. VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. Targeting RET Kinase in Neuroendocrine Prostate Cancer.. Molecular cancer research : MCR, 2020.
35. Diamantopoulos LN, Khaki AR, Grivas P, Gore JL, Schade GR, Hsieh AC, Lee JK, Yezefski T, Yu EY, Schweizer MT, Cheng HH, Psutka SP, Lin DW, Tretiakova MS, Vakar-Lopez F, Montgomery RB, Wright JL. Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.. Bladder cancer (Amsterdam, Netherlands), 2020.
36. DeLucia DC, Lee JK. Identification of Cell Surface Targets for CAR T Cell Immunotherapy.. Methods in molecular biology (Clifton, N.J.), 2020.
37. Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019.
38. Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.. Science translational medicine, 2019.
39. Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman IM, Nelson PS, Dehm SM, LeBeau AM. PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.. Cancer research, 2019.
40. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019.
41. Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.. JCI insight, 2019.
42. Lee JK, Priceman SJ. Precision Medicine-Enabled Cancer Immunotherapy.. Cancer treatment and research, 2019.
43. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.. Science (New York, N.Y.), 2018.
44. Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.. Proceedings of the National Academy of Sciences of the United States of America, 2018.
45. Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017.
46. Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.. Proceedings of the National Academy of Sciences of the United States of America, 2016.
47. Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.. Cell, 2016.
48. Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, Witte ON. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.. Proceedings of the National Academy of Sciences of the United States of America, 2016.
49. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.. Cancer cell, 2016.
50. Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.. Molecular and cellular biology, 2014.
51. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.. Proceedings of the National Academy of Sciences of the United States of America, 2013.
52. Lee JK, Schiller G. Blastic plasmacytoid dendritic cell neoplasm.. Clinical advances in hematology & oncology : H&O, 2012.